FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Tendon & Joint Repair Protocol

Recovery & Healingbeginner
38
Share
ペプチド

2

平均日用量mcg

1,214

レベル

beginner

追加

May 16, 2026

概要

The Tendon and Joint Repair Protocol is a beginner-friendly recovery stack specifically formulated to address the slow-healing connective tissues that plague athletes, active individuals, and anyone dealing with chronic joint or tendon injuries. Tendons and ligaments receive limited blood supply compared to muscles, making them notoriously slow to heal. This two-peptide combination directly addresses that limitation through complementary repair mechanisms. BPC-157, administered at 250mcg twice daily, is a gastric pentadecapeptide with extensive preclinical evidence supporting its role in tendon and ligament repair. Research has demonstrated that BPC-157 accelerates the healing of severed Achilles tendons, torn MCLs, and damaged rotator cuff tissues in animal models. It works by upregulating growth hormone receptors in damaged tissue, promoting angiogenesis to increase blood supply to hypovascular tendons, and stimulating tendon fibroblast proliferation and migration. The twice-daily dosing ensures consistent peptide availability during both the inflammatory and proliferative phases of tendon healing. For localized injuries, subcutaneous injection near the affected tendon yields the best results. TB-500, dosed at 2500mcg twice weekly, complements BPC-157 by promoting cellular migration and reducing inflammation throughout the healing process. As a synthetic fragment of Thymosin Beta-4, it upregulates actin, a cell-building protein essential for tissue repair and new blood vessel formation. TB-500 has a systemic distribution pattern, meaning it reaches injured tissues throughout the body regardless of injection site. It also reduces adhesion formation between healing tissues, promoting more functional and flexible repair rather than stiff scar tissue. Together, these peptides create a powerful healing environment: BPC-157 provides targeted growth factor amplification and local vascularization, while TB-500 ensures system-wide cellular mobility and anti-inflammatory support. This combination is well-suited for tendinitis, tendinosis, ligament sprains, joint capsule injuries, and chronic overuse conditions. The protocol typically runs for 6-8 weeks, with many users reporting noticeable pain reduction and improved mobility within the first 2-3 weeks. As a beginner stack, it requires no complex cycling and carries a favorable safety profile based on available research.

投与プロトコル

250 mcg

1回の投与あたり

2,500 mcg

1回の投与あたり

目標と証拠

証拠ランク:community

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。